Pb2072: efficacy and side effects of ibrutinib in relapsed and refractory mantle cell lymphoma

Background: Mantle cell lymphoma constitutes 6–8% of all B-cell lymphomas. Due to its efficacy and reliability, ibrutinib has been used to treat patients with mantle cell lymphoma who experience a relapse after transplantation, similar to patients with other B-cell malignancies. Aims: The purpose of the present study was to evaluate the efficacy and side effects of ibrutinib in patients with relapsed and refractory mantle cell lymphoma. Methods: This retrospective study included 37 patients with relapse/refractory mantle cell lymphoma who were over the age of 18 years and who were treated in 16 different healthcare centers. The patients’ responsiveness to the administration of ibrutinib, the duration of the response, the prognostic factors affecting the response, and the side effects associated with ibrutinib were analyzed retrospectively. Results: The median follow-up period was eight months. The total response rate was 58% (19.3%, CR). The mean life expectancy was 31.3 months. The mean period to achieve complete remission was four months. While 51.6% of patients responded three months after the initiation of ibrutinib treatment, this rate increased to 56.5% at six months, and to 66.7% at 12 months. In 40.5% of the patients, the duration of treatment was longer than 12 months, and in 13.5% of the patients, it was longer than 24 months. Summary/Conclusion: Our study confirmed the findings of previous studies that the use of ibrutinib in the treatment of R/R MCL was effective and reliable.